A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for <i>EGFR</i> -Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)Hidetoshi Hayashi, Kazuhiko Nakagawa, Satoru Miura et al.|Clinical Cancer Research|2021Cited by 76
A randomized phase II study comparing nivolumab (NIVO) with carboplatin-pemetrexed (CbPEM) for patients (pts) with EGFR mutation-positive non-small cell lung cancer (NSCLC) who acquire resistance to tyrosine kinase inhibitors (TKIs) not due to a secondary T790M mutation (WJOG8515L).Hidetoshi Hayashi, Kazuhiko Nakagawa, Shunichi Sugawara et al.|Journal of Clinical Oncology|2021Cited by 5